Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869713 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
A Phase 2 study of Rift Valley Fever, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT00869713: Completed Phase 2 study of Rift Valley Fever, sponsored by U.S. Army Medical Research and Development Command.
NCT00869713 is a Phase 2 study of Rift Valley Fever that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00869713, a Phase 2 study of Rift Valley Fever, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
Primary Outcome
% vaccinated subjects with PRNT80 ≥ 1:40 after primary series (initial responders).
Conditions Studied
Interventions
- BIOLOGICAL Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Study Locations (1)
Maryland
- U.S. Army Medical Research Institute of Infectious Diseases - Fort Deterick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2009-09 |
| Est. Completion | 2021-05 |
| Phase | Phase 2 |
What the finished NCT00869713 record still lists
NCT00869713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Rift Valley Fever appearing as the primary indexed condition, and to 1 intervention - of which Inactivated, Dried (TSI-GSD 200), RVF Vaccine is the first listed.
NCT00869713 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00869713 about?
NCT00869713 is a clinical study titled "Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated". This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
What is the current status of trial NCT00869713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2009-09. Estimated completion is 2021-05.
What conditions does trial NCT00869713 study?
This clinical trial studies the following conditions: Rift Valley Fever.
What interventions are being tested in trial NCT00869713?
The interventions under investigation include: Inactivated, Dried (TSI-GSD 200), RVF Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00869713?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00869713 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rift Valley Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00869713's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia